Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202.

Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202. Abstract Text:

Arnab Chakravarti,Michelle DeSilvio,Min Zhang,David Grignon,Seth Rosenthal,Sucha O Asbell,Gerald Hanks,Howard M Sandler,Li-Yan Khor,Alan Pollack,William Shipley, ,

PURPOSE: Deregulation of the retinoblastoma (RB) pathway is commonly found in virtually all known human tumors. p16, the upstream regulator of RB, is among the most commonly affected member of this pathway. In the present study, we examined the prognostic value of p16 expression in men with locally advanced prostate cancer who were enrolled on Radiation Therapy Oncology Group protocol 9202. PATIENTS AND METHODS: RTOG 9202 was a phase III randomized study comparing long-term (LT) versus short-term (ST) androgen-deprivation therapy (AD). Of the 1,514 eligible cases, 612 patients had adequate tumor material for p16 analysis. Expression levels of p16 were determined by immunohistochemistry (IHC). IHC staining was scored quantitatively using an image analysis system. RESULTS: On multivariate analysis, intact p16 expression was significantly associated with decreased rate of distant metastases (P = .0332) when both STAD and LTAD treatment arms were considered together. For patients with intact (high levels of immunostaining) p16 (mean p16 index > 81.3%), LTAD plus radiotherapy (RT) significantly improved prostate cancer survival (PCS) compared with STAD plus RT (P = .0008) and reduced the frequency of distant metastasis (P = .0069) compared with STAD plus RT. In contrast, for patients with tumors demonstrating p16 loss (low levels of immunostaining, mean p16 index < or = 81.3%), LTAD plus RT significantly improved biochemical no evidence of disease survival over STAD (P < .0001) primarily by decreasing the frequency of local progression (P = .02), as opposed to distant metastasis, which was the case in the high-p16 cohort. CONCLUSION: Low levels of p16 on image analysis appear to be associated with a significantly higher risk of distant metastases among all study patients. p16 expression levels also appear to identify patients with locally advanced prostate cancer with distinct patterns of failure after LTAD.

Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202. Publishing Authors By Initials

A Chakravarti,M DeSilvio,M Zhang,D Grignon,S Rosenthal,SO Asbell,G Hanks,HM Sandler,LY Khor,A Pollack,W Shipley, ,

For similar biological factors: biological markers: tumor markers, biological research abstracts see: biological factors: biological markers: tumor markers, biological research

PUBMED ID PMID:

MEDLINE DATE:

Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Journal of clinical oncology : official journal of

VOLUME: 25

Page Numbers: 3082-9

Journal Abbreviation: J. Clin. Oncol.

ISSN: 1527-7755

DAY: 20

MONTH: Jul

YEAR: 2007

Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8309333

Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202. Keywords Mesh Terms:

KEYWORDS: Tumor Markers, Biological

MESH TERMS: blood

Chemical & Substance for Abstract: Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202. Information

Substance Name: Prostate-Specific Antigen

Registry Number: EC 3.4.21.77

Grant and Affiliation Information for Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202.

AFFILIATION: Massachusetts General Hospital/Harvard Medical School, Department of Radiation Oncology, Boston, MA 02114, USA. achakravarti@partners.org

Country: United States

AGENCY: United States NCI

GRANT: U10CA37422

ACRONYM: CA

MEDLINETA: J Clin Oncol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202 Related Publications

• A hierarchy of distress: Mokken scaling of the GHQ-30.
• A theory of dynamic occluded and illusory object perception.
• Chromosomal imbalances in pleomorphic rhabdomyosarcomas and identification of the alveolar rhabdomyosarcoma-associated PAX3-FOXO1A fusion gene in one case.
• Cigarette smoking and site-specific cancer mortality: testing uncertain associations using extended follow-up of the original Whitehall study.
• Clinical relevance of molecular genetics to paediatric sarcomas.
• Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.
• Computed tomography of localized pleural mesothelioma.
• Digital ischaemia: vasculitis vs trauma.
• ECT, sleep, and biogenic amines in affective illness.
• EFFECTIVENESS OF TOPICAL APPLICATION OF A NUMBER OF PROGESTINS.
• Fluorescence and chromogenic in situ hybridization to detect genetic aberrations in formalin-fixed paraffin embedded material, including tissue microarrays.
• Genes, chromosomes and the development of testicular germ cell tumors of adolescents and adults.
• Genomic copy number and expression patterns in testicular germ cell tumours.
• Guinea pig copulatory reflex in response to adrenal steroids and similar compounds.
• HEALTH ADMINISTRATION ON THE DISTRICT PLAN.
• Long-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: analysis of radiation therapy oncology group studies 85-31, 86-10, and 92-02.
• Malignant tumors of the cheek in children; report of two cases.
• Monitoring of antidepressant response to ECT with polysomnographic recordings and the dexamethasone suppression test.
• Mortality and associated risk factors in diabetics.
• Multiple conductances cooperatively regulate spontaneous bursting in mouse olfactory bulb external tufted cells.
• Novel formation and amplification of the PAX7-FKHR fusion gene in a case of alveolar rhabdomyosarcoma.
• Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202.
• Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison.
• Response to: "Spinal cord stimulation: stimulating questions".
• Synchronization of estrus in early diestral dairy heifers with Prostaglandin F(2)alpha and estradiol benzoate.
• Ten-Year Follow-Up of Radiation Therapy Oncology Group Protocol 92-02: A Phase III Trial of the Duration of Elective Androgen Deprivation in Locally Advanced Prostate Cancer.
• The effect of steroid hormone on the fatty liver induced in rats by dietary means.
• The gonads and aging.
• Thyroidal uptake of I131 after iopanoic acid (telepaque) in 74 subjects.
• Ultraviolet DIAL measurements of O3 profiles in regions of spatially inhomogeneous aerosols.